Does the Serum Immuno-Inflammation Index, Guide the Treatment of Medium and High Risk Pulmonary Thromboembolism Patients? SERUM İMMÜN-İNFLAMASYON İNDEKSİ ORTA VE YÜKSEK RİSKLİ PULMONER TROMBOEMBOLİ HASTALARININ TEDAVİSİNDE YOL GÖSTERİCİ MİDİR?
Journal of Kirikkale University Faculty of Medicine, cilt.26, sa.2, ss.169-174, 2024 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 26 Sayı: 2
- Basım Tarihi: 2024
- Doi Numarası: 10.24938/kutfd.1434903
- Dergi Adı: Journal of Kirikkale University Faculty of Medicine
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.169-174
- Anahtar Kelimeler: Pulmonary embolism, reperfusion, serum immune inflammation index
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: Pulmonary thromboembolism(PTE) is an emergency condition with high mortality, although it has effective treatment. Most deaths occur in the first hour. Therefore, early diagnosis is lifesaving. Serum immune-inflammation index (SII) is a parameter derived from neutrophils, lymphocytes and platelets. It has been reported to be an important biomarker determining mortality in ischemic diseases. In this article, we aimed to evaluate the role of easily accessible and rapid SII in predicting thrombolytic therapy. Material and Methods: This study was conducted retrospectively in the single-center Health Sciences University Dışkapı Yıldırım Beyazıt Training and Research Hospital Emergency Service, in patients diagnosed with medium and high risk PTE between 01.10.2020 and 01.08.2022. The patients vitals at the time of admission and routine blood tests were evaluated. Risk groups were determined with imaging and echocardiography findings. Treatment and outcomes for PTE were recorded. Results: 204 patients were included in the study. 63.7% of the patients were women. The average age of the patients was 71.7 years. 33 (16.1%) of the patients died within 30 days of follow-up. 28.9% of the patients were included in the high risk group. 30% were in the medium-high risk group and 41.1% were in the medium-low risk group. 49 (24%) patients included in the study required thrombolytic therapy. The cut-off value for SII was determined as 2187, with 34.7% sensitivity and 96.1% specificity. SII was found to be predictive of the need for thrombolytic therapy (AUC: 0.615, 95% CI 0.513-0.717, p<0.001). Conclusion: The serum immune-inflammation index, which is a rapid and easily accessible biomarker, is a guide in determining patients in need of thrombolysis.